The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
For decades, cytotoxic therapy was considered ineffective for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Earlier therapies such as estramustine and mitoxantrone received regulatory approval based upon improvement in palliative endpoints. In 2004, docetaxel became the f...
Main Authors: | Che-Kai Tsao, Elena Cutting, Jacob Martin, William K. Oh |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-06-01
|
Series: | Therapeutic Advances in Urology |
Online Access: | https://doi.org/10.1177/1756287214528557 |
Similar Items
-
Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
by: Che-Kai Tsao, et al.
Published: (2011-01-01) -
Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
by: Cedric Pobel, et al.
Published: (2021-09-01) -
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
by: Channing J Paller, et al.
Published: (2011-03-01) -
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
by: Patel SA, et al.
Published: (2017-08-01) -
Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
by: Bahram Mofid, et al.
Published: (2015-05-01)